Financials
Financial year 2025
Revenue
€ 76.6 million
▲ 5% vs 2024
Profit
Healthy€ 2.1 million
▼ 13% vs 2024
Debts
Low€ 20.2 million
▼ 8% vs 2024
BOSTON SCIENTIFIC BENELUX from Machelen (Brab.), company number BE0450258756, closed financial year 2025 with a result of € 2.1 million after tax. For that financial year BOSTON SCIENTIFIC BENELUX recorded revenue of € 76.6 million and equity of € 13 million. Compared with financial year 2024, the result moved from € 2.5 million to € 2.1 million. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 2, 2026.
What happened at BOSTON SCIENTIFIC BENELUX?
What happened at BOSTON SCIENTIFIC BENELUX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Woodworth Emily stepped down as director. NBB
- J. Cronin Douglas stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 2.1 million (▼ 13% vs 2024). Source: NBB ↗
- Woodworth Emily became a director. NBB
- J. Cronin Douglas became a director. NBB
- New establishment in Machelen (Brab.). KBO
- Start of the company according to the CBE. KBO
In short
From € 1.6 million profit in 2021 to € 2.1 million profit in 2025.
Paid € 4.5 million in corporate taxes since 2021.
Best year ever: 2024, with € 2.5 million profit.
Pays suppliers within 78 days on average.
A new publication or filing at BOSTON SCIENTIFIC BENELUX? We notify you, reason included.
Follow BOSTON SCIENTIFIC BENELUXNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
The shares are held by Boston Scientific International B.V. (100%) and Target Therapeutics, Inc. (0%).
Directors
According to the 2025 annual accounts
since 2024 · until 2030
J. Cronin Douglas
Director
since 2024 · until 2030
Shareholders
Boston Scientific International B.V.
100%
Target Therapeutics, Inc.
0%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Lambroekstraat 5D
1831 Machelen (Brab.)
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 16 companies are registered at this address.
Guidant Europe same network
€ 22.5 million revenue · 2025
SOFINDEV V
€ -2.1 million gross margin · 2025
SMGX
FPI Partners
Sofindev VI Investments (Privak)
+11 more
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
AMAZON-02 - Amazon.com, Inc., US
Domain
Domain
bostonscientific.com
Registered
1996-05-03
Registrar
CSC Corporate Domains, Inc.
Expires
2026-05-04
Website info
Features
Security
Network
Details
- Company number
- 0450.258.756
- VAT number
- BE 0450.258.756
- Registered office
- Lambroekstraat 5D, 1831 Machelen (Brab.)
- Names & denominations
- BOSTON SCIENTIFIC BENELUX
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 2 June 1993
- Peppol
- Active · Active since 8 Sept 2022
- Contact
- bostonscientific.com
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten
Handelsbemiddeling gespecialiseerd in overige goederen, n.e.g.
Handelsbemiddeling in de groothandel in andere specifieke goederen
Vervaardiging van niet-elektrische apparaten en instrumenten voor de geneeskunde, de tandheelkunde en de veeartsenijkunde
Vervaardiging van medische en tandheelkundige instrumenten en benodigdheden